Joseph Anthony Murray

Joseph Anthony Murray

Auto-generated profile, based on publicly available information

Joseph Anthony Murray

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2012 in Gut
Verified
Journal Article
Open access
PDF file
JLJohnny Ludvigsson
Johnny Ludvigsson
DLDaniel A Leffler
Daniel A Leffler
JBJulio C Bai
Julio C Bai
FBFederico Biagi
Federico Biagi
AFAlessio Fasano
Alessio Fasano
Carolina CiacciCarolina Ciacci
Carolina Ciacci
Objective The literature suggests a lack of consensus on the use of terms related to coeliac disease (CD) and gluten. Design A multidisciplinary task force of 16 physicians from seven countries used the electronic database PubMed to review the literature for CD-related terms up to January 2011. Teams of physicians then suggested a definition for each term, followed by feedback of these definitions through a web survey on definitions, discussions during a meeting in Oslo and phone conferences. In addition to ‘CD’, the following descriptors of CD were evaluated (in alphabetical order): asymptomatic, atypical, classical, latent, non-classical, overt, paediatric classical, potential, refractory, silent, subclinical, symptomatic, typical, CD serology, CD autoimmunity, genetically at risk of CD, dermatitis herpetiformis, gluten, gluten ataxia, gluten intolerance, gluten sensitivity and gliadin-specific antibodies. Results CD was defined as ‘a chronic small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed individuals’. Classical CD was defined as ‘CD presenting with signs and symptoms of malabsorption. Diarrhoea, steatorrhoea, weight loss or growth failure is required.’ ‘Gluten-related disorders’ is the suggested umbrella term for all diseases triggered by gluten and the term gluten intolerance should not to be used. Other definitions are presented in the paper. Conclusion This paper presents the Oslo definitions for CD-related terms.

1 May 2013 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
ARAlberto Rubio-Tapia
Alberto Rubio-Tapia
IHIvor D Hill
Ivor D Hill
CKCiarán P Kelly
Ciarán P Kelly
ACAudrey H Calderwood
Audrey H Calderwood
JMJoseph A Murray
Joseph A Murray
Resolves with exclusion of gluten from the diet. There has been a substantial increase in the prevalence of celiac disease over the last 50 years and an increase in the rate of diagnosis in the last 10 years. Celiac disease can present with many symptoms, including typical gastrointestinal symptoms (e.g., diarrhea, steatorrhea, weight loss, bloating, flatulence, abdominal pain) and also non-gastrointestinal abnormalities (e.g., abnormal liver function tests, iron deficiency anemia, bone disease, skin disorders, and many other protean manifestations). Indeed, many individuals with celiac disease may have no symptoms at all. Celiac disease is usually detected by serologic testing of celiac-specific antibodies. The diagnosis is confirmed by duodenal mucosal biopsies. Both serology and biopsy should be performed on a gluten-containing diet. The treatment for celiac disease is primarily a gluten-free diet (GFD), which requires significant patient education, motivation, and follow-up. Non-responsive celiac disease occurs frequently, particularly in those diagnosed in adulthood. Persistent or recurring symptoms should lead to a review of the patient's original diagnosis to exclude alternative diagnoses, a review of the GFD to ensure there is no obvious gluten contamination, and serologic testing to confirm adherence with the GFD. In addition, evaluation for disorders associated with celiac disease that could cause persistent symptoms, such as microscopic colitis, pancreatic exocrine dysfunction, and complications of celiac disease, such as enteropathy-associated lymphoma or refractory celiac disease, should be entertained. Newer therapeutic modalities are being studied in clinical trials, but are not yet approved for use in practice. Given the incomplete response of many patients to a GFD-free diet as well as the difficulty of adherence to the GFD over the long term, development of new effective therapies for symptom control and reversal of inflammation and organ damage are needed. The prevalence of celiac disease is increasing worldwide and many patients with celiac disease remain undiagnosed, highlighting the need for improved strategies in the future for the optimal detection of patients....

10 February 2003 in Archives of internal medicine (1960)
Verified
Journal Article
Closed access
PDF file
Alessio FasanoAlessio Fasano
Alessio Fasano
IBIrene Berti
Irene Berti
TGTania Gerarduzzi
Tania Gerarduzzi
TNTarcisio Not
Tarcisio Not
RCRichard B. Colletti
Richard B. Colletti
KHKaroly Horvath
Karoly Horvath
Research from JAMA Internal Medicine — Prevalence of Celiac Disease in At-Risk and Not-At-Risk Groups in the United States — A Large Multicenter Study

28 February 2010 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PDPatrick C A Dubois
Patrick C A Dubois
GTGosia Trynka
Gosia Trynka
LFLude Franke
Lude Franke
KHKaren A Hunt
Karen A Hunt
JRJihane Romanos
Jihane Romanos
DHDavid A van Heel
David A van Heel
David van Heel and colleagues report results of a large genome-wide association study of celiac disease. Most of the associated loci contain genes with immune functions, and over half harbor risk variants that are correlated with variation in cis gene expression. We performed a second-generation genome-wide association study of 4,533 individuals with celiac disease (cases) and 10,750 control subjects. We genotyped 113 selected SNPs with PGWAS < 10−4 and 18 SNPs from 14 known loci in a further 4,918 cases and 5,684 controls. Variants from 13 new regions reached genome-wide significance (Pcombined < 5 × 10−8); most contain genes with immune functions (BACH2, CCR4, CD80, CIITA-SOCS1-CLEC16A, ICOSLG and ZMIZ1), with ETS1, RUNX3, THEMIS and TNFRSF14 having key roles in thymic T-cell selection. There was evidence to suggest associations for a further 13 regions. In an expression quantitative trait meta-analysis of 1,469 whole blood samples, 20 of 38 (52.6%) tested loci had celiac risk variants correlated (P < 0.0028, FDR 5%) with cis gene expression.

21 April 2016 in Genome Medicine
Verified
Journal Article
Open access
PDF file
JCJun Chen
Jun Chen
KWKerry Wright
Kerry Wright
JDJohn M. Davis
John M. Davis
PJPatricio Jeraldo
Patricio Jeraldo
EMEric V. Marietta
Eric V. Marietta
VTVeena Taneja
Veena Taneja
The adaptive immune response in rheumatoid arthritis (RA) is influenced by an interaction between host genetics and environment, particularly the host microbiome. Association of the gut microbiota with various diseases has been reported, though the specific components of the microbiota that affect the host response leading to disease remain unknown. However, there is limited information on the role of gut microbiota in RA. In this study we aimed to define a microbial and metabolite profile that could predict disease status. In addition, we aimed to generate a humanized model of arthritis to confirm the RA-associated microbe. To identify an RA biomarker profile, the 16S ribosomal DNA of fecal samples from RA patients, first-degree relatives (to rule out environment/background as confounding factors), and random healthy non-RA controls were sequenced. Analysis of metabolites and their association with specific taxa was performed to investigate a potential mechanistic link. The role of an RA-associated microbe was confirmed using a human epithelial cell line and a humanized mouse model of arthritis. Patients with RA exhibited decreased gut microbial diversity compared with controls, which correlated with disease duration and autoantibody levels. A taxon-level analysis suggested an expansion of rare taxa, Actinobacteria, with a decrease in abundant taxa in patients with RA compared with controls. Prediction models based on the random forests algorithm suggested that three genera, Collinsella, Eggerthella, and Faecalibacterium, segregated with RA. The abundance of Collinsella correlated strongly with high levels of alpha-aminoadipic acid and asparagine as well as production of the proinflammatory cytokine IL-17A. A role for Collinsella in altering gut permeability and disease severity was confirmed in experimental arthritis. These observations suggest dysbiosis in RA patients resulting from the abundance of certain rare bacterial lineages. A correlation between the intestinal microbiota and metabolic signatures could determine a predictive profile for disease causation and progression.

1 January 2005 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
IHIvor D. Hill
Ivor D. Hill
MDMartha H. Dirks
Martha H. Dirks
GLGregory S. Liptak
Gregory S. Liptak
RCRichard B. Colletti
Richard B. Colletti
AFAlessio Fasano
Alessio Fasano
ESErnest G. Seidman
Ernest G. Seidman